Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4280 - Survival patterns of high-grade breast cancer patients in the United States

Date

10 Oct 2016

Session

Poster display

Presenters

Mohammed Mousa

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

M. Mousa1, A. Meshref1, M. Ramadan1, M.Y. Haggag2

Author affiliations

  • 1 Faculty Of Medicine, Suez Canal University, 41522 - Ismailia/EG
  • 2 Faculty Of Medicine, Suez Canal University, 42524 - Ismailia/EG
More

Resources

Abstract 4280

Background

Our study aimed at evaluation of relative survival rates of patients with high-grade breast in the United States diagnosed in 2010 using the Surveillance, Epidemiology, and End Results (SEER) Registry.

Methods

We used Kaplan-Meir method to analyze the 2-year relative survival rates of 14283 Bloom-Richardson grade III breast cancer patients using SEER*Stat Program. We used Z-test to compare relative survival rates among patients' groups categorized by radiation therapy status, age groups, race, site, histology, Her2/Hormone Receptors (HR) status, and laterality using Z–test. We used Kaplan-Meir method to analyze the 2-year relative survival rates of 14283 Bloom-Richardson grade III breast cancer patients using SEER*Stat Program. We used Z-test to compare relative survival rates among patients' groups categorized by radiation therapy status, age groups, race, site, histology, Her2/Hormone Receptors (HR) status, and laterality using Z–test.

Results

There was a statistically significant increase in the 2-year relative survival rate for patients who received radiation therapy (96.8 ± 0.3%) in comparison to patients who did not receive it (89.3 ± 0.4%, P 

Conclusions

Radiation therapy, patient's age, race, site, histology, Her2/HR status can affect the relative survival rates in high-grade breast cancer cases while laterality seems to have no effect on relative survival in such cases. These findings can be used in designing better disease surveillance and prognostic counseling programs.

Clinical trial identification

Legal entity responsible for the study

American National Cancer Institute, The Surveillance, Epidemiology, and End Results (SEER) Program

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings